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Abstract 
In Tangier disease, absence of ATP binding cassette transporter A1 (ABCA1) results in reduced 
plasma HDL and elevated triglyceride (TG) levels. We hypothesized that hepatocyte ABCA1 
regulates VLDL TG secretion through nascent HDL production. Silencing of ABCA1 expression 
in oleate-stimulated rat hepatoma cells resulted in: 1) decreased large nascent HDL (>10 nm 
diameter) and increased small nascent HDL (<10 nm) formation, 2) increased large buoyant 
VLDL1 particle secretion, and 3) decreased phosphatidylinositol-3 (PI3) kinase activation. 
Nascent HDL-containing conditioned medium from rat hepatoma cells or HEK293 cells 
transfected with ABCA1 was effective in increasing PI3 kinase activation and reducing VLDL TG 
secretion in ABCA1-silenced hepatoma cells. Addition of isolated large nascent HDL particles to 
ABCA1-silenced hepatoma cells inhibited VLDL TG secretion to a greater extent than small 
nascent HDL. Similarly, addition of recombinant HDL, but not human plasma HDL, was effective 
in attenuating TG secretion and increasing PI3 kinase activation in ABCA1-silenced cells. 
Collectively, these data suggest that large nascent HDL particles, assembled by hepatic ABCA1, 
generate a PI3 kinase-mediated autocrine signal that attenuates VLDL maturation and TG 
secretion. This pathway may explain the elevated plasma TG concentration that occurs in most 
Tangier subjects and may also account, in part, for the inverse relationship between plasma HDL 
and TG concentrations in individuals with compromised ABCA1 function. 
Keywords: hepatic ATP binding cassette transporter A1, very low density lipoprotein TG 
secretion, PI3 kinase signaling, ABCA1 silencing, Tangier disease, VLDL assembly 
 
ABCA1 is a membrane protein that transports phospholipid (PL) and free cholesterol (FC) across 
cell membranes, to combine with lipid-free apolipoprotein (apo)A-I , forming nascent HDL 
particles (1). Mutations in ABCA1 that inactivate its function cause Tangier disease, which is 
characterized by a severe HDL deficiency, rapid clearance of apoA-I from plasma, deposition of 
sterol in macrophage-rich tissues, and premature coronary heart disease (2–5). ABCA1 is 
expressed in many cells, but hepatocytes are the single most important cell type in determining 
plasma HDL concentrations, contributing 70–80% of the HDL pool in mice (6, 7). Recently, we 
have shown that ABCA1 expression is necessary and sufficient for formation of heterogeneous-
sized pre-β migrating nascent HDL subspecies (pre-β 1, 2, 3, and 4 HDL), which vary in size from 
7.1 to 15.7 nm (8). Although electrophoretic mobility (pre-β vs. α migration) of discoidal nascent 
HDLs is dependent on cell type and culture conditions, similar distinct-sized subspecies of nascent 
HDL are formed by most cell types tested, including fibroblasts (9, 10), macrophages, hepatocytes, 
and ABCA1-expressing human embryonic kidney (HEK)293 cells (11). The importance of nascent 
HDL size heterogeneity in the physiology and pathophysiology of HDL metabolism is poorly 
understood. 
ABCA1 expression also affects plasma VLDL and LDL concentrations. In addition to the near 
absence of plasma HDL, many homozygous Tangier disease patients have variable and 
significantly elevated plasma TG levels as well as reduced LDL concentrations compared with 
normal controls (2). Similarly, heterozygous Tangier disease patients have decreased HDL 
cholesterol (HDL-C) and elevated plasma TG levels, but similar plasma LDL concentrations 
compared with controls (12). Recently, our group documented that targeted deletion of ABCA1 in 
hepatocytes resulted in many of the phenotypic manifestations of Tangier disease including: 1) 
severe reduction in plasma HDL (∼20% of normal), 2) reduced (50%) plasma LDL concentrations, 
3) increased (2-fold) plasma TG concentrations, and 4) hypercatabolism of apoA-I (6), suggesting 
that hepatic ABCA1 plays a major role in determining the Tangier disease plasma lipid phenotype, 
including the higher plasma TG concentrations. It has been suggested that apoC-III and apoA-II 
enrichment of VLDL results in reduced reactivity with lipoprotein lipase in Tangier subjects (2, 
13, 14), leading to increased plasma TG concentrations. Another study has shown that incubation 
of apoA-I with wild-type, but not ABCA1 knockout, mouse hepatocytes results in decreased 
secretion of newly synthesized TG, suggesting an inverse relationship between apoA-I-mediated 
lipid efflux via hepatic ABCA1 and TG secretion (15). However, the underlying mechanism 
relating ABCA1 deficiency to elevated plasma TG concentrations and hepatic VLDL secretion is 
poorly understood. 
Although liver is a major organ for both HDL and VLDL production, there is no evidence for a 
direct role of ABCA1 in modulating TG mobilization for nascent VLDL particle assembly. In this 
work, we hypothesized that loss of ABCA1 function increases VLDL TG secretion indirectly via 
nascent HDL, the product of ABCA1 activity. Our data suggest that pre-β migrating nascent HDL 
particles, assembled by ABCA1, generate a phosphatidylinositol-3 (PI3) kinase-mediated signal 
that attenuates hepatic VLDL maturation and TG secretion. 
 
Experimental Procedures 
Cell culture and siRNA transfection 
Rat hepatoma McA-RH7777 (McA) cells were cultured in DMEM containing 10% FBS, 2 mM L-
glutamine, 100 units/ml penicillin, and 100 μg/ml streptomycin in 5% CO2 at 37°C. Control and 
ABCA1 over-expressing HEK293 cells were cultured as described previously (8). Where 
indicated, 0.8 mM sodium oleate complexed to 0.5% BSA was included in culture medium. 
McA cells were seeded at ∼70% confluence and after overnight culture transfected with 25 nM rat 
ABCA1 ON-TARGET plus SMARTpool small interfering (si)RNA (Dharmacon) or 25 nM 
negative control siRNA (AllStars Negative, Qiagen) using DharmaFECT1 siRNA transfection 
reagent according to the manufacturer's protocol. Forty-eight h after siRNA transfection, McA 
cells were incubated with oleate or lipid-free apoA-I for an additional 12–24 h as described below. 
Promoter reporter assay for LXR activity 
Two days after transfection with siRNA, McA cells were transiently transfected with 0.2 μg of 
pCMX-Gal4-LXRαLBD, an expression vector containing liver X receptor (LXR)α ligand binding 
domain (amino acid 155-447), and 0.2 μg of pMH100 × 4-TK-Luc, a luciferase reporter construct 
(16, 17), and 1 ng of pRL-CMV, a control vector, using Fugen-6 reagent (Roche Applied Science) 
according to the manufacturer's protocol. Cells were then incubated in DMEM supplemented with 
3% charcoal-stripped serum in the presence and absence of oleate (0.8 mM, Sigma) or T0901317 
(5 μM, Sigma) stimulation. After 16 h, the cells were harvested and the luciferase assay was 
performed using the commercial kits for dual luciferase assay (Promega). 
Analysis of radiolabeled TG secretion 
Two days after transfection with siRNA, McA cells were incubated with [3H]oleate (10 μCi/ml, 
Perkin Elmer Life Sciences) ± 0.8 mM oleate (complexed with BSA, fatty acid: BSA molar ratio 
= 5:1) in radiolabeling medium composed of four parts Met/Cys-deficient DMEM and one part 
complete DMEM in 5% FBS (18). For the kinetic studies shown in Fig. 1F, siRNA transfected 
McA cells were pulse-radiolabeled with 1 μCi/ml [14C]glycerol and 5 μCi/ml [3H]acetate (Perkin 
Elmer Life Sciences) in the same radiolabeling medium. For inhibition of PI3 kinase activity, 
transfected McA cells were pretreated for 1 h with either 100 nM wortmannin (Calbiochem), 10 
μM LY294002 (Calbiochem), or DMSO vehicle (control) before stimulation with [3H]oleate (10 
μCi/ml) plus 0.8 mM oleate. For experiments in which nascent HDL formation and VLDL-TG 
secretion were both monitored (Figs. 4, ,5),5), transfected McA cells were washed with balanced 
salt solution and the medium was changed to serum-free DMEM containing lipid-free [125I]apoA-
I and [3H]oleate (10 μCi/ml) plus 0.8 mM oleate. 
After the cells were incubated for 12–24 h, lipids were extracted using the Bligh Dyer method (19) 
and separated by a dual-solvent TLC system. Briefly, the lipid extract was first developed in a 
polar solvent system (chloroform: methanol: acetic acid: water = 75:45:12:6) until the solvent front 
had traveled above the origin (∼5 cm), to ensure that any residual unincorporated radiolabel tracer 
would remain at the origin and not contaminate the phospholipid fraction. Then, the plate was 
allowed to dry and placed in a neutral solvent system (hexane: ether: acetic acid = 70:30:2). Based 
on the migration of authentic lipid standards, bands corresponding to PL, FC, FFA, TG, and 
cholesteryl ester (CE) were cut and [3H] and/or [14C] radioactivity quantified by liquid scintillation 
spectroscopy. After lipid extraction, cellular protein was assayed by the Lowry method and results 
were expressed as dpm/μg cell protein. 
Western blotting 
Immunoblotting of ABCA1 and β-actin were conducted as we previously described using 4–16% 
gradient SDS-PAGE (6). All the other proteins were separated using 10% SDS-PAGE. After 
electrophoresis, proteins were transferred to a polyvinylidene difluoride (PVDF) membrane for 
conventional Western blotting. The polyclonal antibodies targeting p-PI3K p55/p85, p-AKT 
(protein kinase B) (Ser473), p-AKT (Thr308), p-phosphoinositide-dependent kinase-1 (PDK1) 
(Ser241), p-extracellular signal-regulated kinase (ERK) (Thr202 /Tyr204), p-cJun NH2-terminal 
kinase (JNK) (Thr183/Tyr185), t-ERK, and p-mammalian target of rapamycin (mTOR) (Ser2448) 
were purchased from Cell Signaling Technology. Monoclonal antibody against adipocyte 
differentiation related protein (ADRP) was purchased from Research Diagnostics, Inc. Goat 
antibody against bovine large subunit 88 of microsomal triglyceride transfer protein (MTP) (α88-
MTP) was a gift from Dr. David Gordon at Bristol-Myers Squibb. 
Immunoprecipitation of apoB 
For metabolic radiolabeling of apoB, siRNA transfected McA cells were preincubated in Met/Cys-
deficient medium for 30 min. The medium was changed to labeling medium containing 50 μCi/ml 
of [35S]Met/Cys (Perkin Elmer Life Sciences) in the presence of 0.8 mM oleate for 4 h. ApoB in 
total cell extracts and medium was immunoprecipitated with 5 μl of goat anti-human apoB 
antibody (Academy Bio-Medical Co.) in immunoprecipitation buffer [1% Triton X-100, 0.5% NP 
40, 150 mM NaCl, 1 mM EDTA, protease and phosphatase inhibitors (Sigma) in 10 mM Tris 
buffer (pH 7.4)]. The samples were then incubated with rotation at 4°C for 18 h, after which 20 μl 
of protein G-Sepharose beads (Amersham 50:50 slurry) were added and the incubation was 
continued for an additional 2 h at 4°C. Beads were collected by centrifugation at 10,000 rpm for 
20 s and washed three times with immunoprecipitation buffer. Proteins were eluted from the beads 
by heating (70°C for 15 min) in 1× SDS-PAGE sample buffer with DTT and subjected to 4–8% 
gradient SDS-PAGE. The dried gel was visualized using a phosphorimager. 
Density gradient ultracentrifugation of ApoB-containing lipoproteins 
Transfected McA cells (3 × 106 cells in 10 cm plate) were radiolabeled with [35S]Met/Cys for 4 h. 
ApoB-containing lipoproteins in the conditioned medium were separated by cumulative rate 
flotation ultracentrifugation as described by Wang et al. (20). Briefly, 4 ml of the sample, adjusted 
to d = 1.10 g/ml with solid KBr, was overlaid with 3 ml of d = 1.065 g/ml NaBr, 3 ml of d = 1.02 
g/ml NaBr, and 3 ml of d = 1.006 g/ml NaCl in a Beckman SW40 centrifuge tube. After 
centrifugation at 40,000 rpm for 148 min at 20°C, VLDL1 (Sf > 100) was collected as the top 1 ml 
of the gradient. Following subsequent centrifugation at 37,000 rpm for 18 h at 15°C, VLDL2 (Sf 
20–100) and the other lipoproteins were collected from the top into 12 one-ml fractions. ApoB in 
individual fractions or pooled fractions was immunoprecipitated, resolved by SDS-PAGE, and 
visualized using a phosphorimager. 
Lipoprotein size analysis 
To determine the size of VLDL particles secreted from McA cells, 5 ml of conditioned medium 
from 3 × 106 cells incubated for 24 h were concentrated to 0.5 ml using an Amicon Ultra-10 
concentrator. The concentrated VLDL fraction was overlayered with saline and spun at 100,000 g 
for 4 h to float the VLDL, which was then collected by tube-slicing. The volume was adjusted to 
0.5 ml and the VLDL analyzed using a Zetasizer nano S® dynamic light scattering instrument 
(Malvern). Particle sizes are reported as median peak diameter using volume analysis. 
Nascent HDL formation 
Lipid-free apoA-I was prepared and radiolabeled as previously described (8) and verified to be 
authentic human apoA-I by mass spectrometry (21) and SDS-PAGE analysis. ApoA-I preparations 
contained <1 molecule of PL per molecule of apoA-I as assessed by phosphorus analysis (22). 
siRNA-transfected McA cells or ABCA1-expressing HEK were incubated with 10 μg/ml of lipid-
free [125I]apoA-I (105 cpm/μg) in serum-free medium for 24 h. Immediately before incubation, 
[125I]apoA-I was heated to 60°C for 30 min and then cooled to room temperature to standardize 
the conformational state of apoA-I (8, 23). The size distribution of nascent HDL particles in 
conditioned medium was determined by 4–30% nondenaturing gradient gel (NDGGE) at 10°C for 
1,400 V/h. After electrophoresis, gels were imaged using a phosphorimager to visualize the 
nascent HDL. To determine the electrophoretic mobility of McA cell-generated nascent HDL 
particles, 15 μl of medium was analyzed using a Paragon lipoprotein agarose gel electrophoresis 
system (Beckman), according to the manufacturer's instructions. The remainder of the conditioned 
medium was fractionated by size-exclusion chromatography using three Superdex 200 HR fast 
protein liquid chromatography (FPLC) columns in series as described previously (8). 
rHDL preparation and human HDL isolation 
Recombinant (r)HDLs were prepared from lipid free apoA-I and egg yolk PC using a cholate 
dialysis procedure as described previously (24). To obtain different sized rHDL particles, initial 
apoA-I to PC molar ratios of 1:30 for small rHDL (< 9.6 nm, rHDLsm) and 1:160 for large rHDL 
(>9.6 nm, rHDLlg) were used. After extensive dialysis to remove cholate, electrophoretic mobility 
and rHDL particle size were determined using agarose gel electrophoresis and NDGGE (4–30%), 
respectively (8). rHDLs were used for experiments without further purification. To isolate human 
HDL (hHDL), human plasma lipoproteins were isolated by ultracentrifugation at d<1.25g/ml and 
lipoproteins were fractionated by FPLC using a Superose 6 column. The peak three fractions of 
the HDL elution region were pooled and used for experiments. 
Statistical analyses 
Results are presented as mean ± SEM. Data were statistically analyzed using Student's t-test or 
one way ANOVA with Tukey's multiple comparison test to isolate individual differences. 
Analyses were performed using GraphPad® Prism software. 
Results 
Silencing of ABCA1 in McA rat hepatoma cells increases VLDL TG secretion 
McA cells were chosen for these studies because they robustly secrete VLDL upon incubation 
with oleic acid (20, 25). In addition, McA cells incubated with apoA-I assemble nascent HDL 
particles that are similar in size to the discrete-sized populations of nascent HDL assembled by 
HEK293 cells expressing ABCA1 (11). 
To reduce ABCA1 expression in McA cells, we used siRNA. A dose-response study demonstrated 
that ABCA1 expression was reduced by ∼70% after transfection with 25–100 nM ABCA1 siRNA 
compared with two different control siRNAs (Fig. 1A). For all subsequent studies, we used 25 nM 
siRNA. To determine the effect of ABCA1 silencing on secretion of newly synthesized TG, 
[3H]oleate was added to control or ABCA1-silenced McA cells in the presence of 0.8 mM oleate 
to stimulate VLDL secretion. In agreement with a previous study (26), <5% of newly synthesized 
TG was secreted into the medium, whereas the remainder was cell associated (Fig. 1B). Compared 
with control, silencing of ABCA1 was associated with a ∼2-fold increase in TG secretion (Fig. 
1B). However, the amount of radiolabel incorporated into cellular TG was similar between control 
and ABCA1 siRNA transfected cells. The TG increase observed in whole medium upon silencing 
of ABCA1 was confined to the VLDL peak as shown by FPLC analysis (Fig. 1C). 
To further investigate the kinetics of lipid synthesis and secretion with ABCA1 silencing, McA 
cells were pulse radiolabeled with [3H]acetic acid and [14C]glycerol in the presence of oleate (0.8 
mM) and the incorporation of radiolabel into newly synthesized lipid in the cells and secretion into 
medium was followed for 24 h (Fig. 1D). Silencing of ABCA1 was associated with decreased 
[3H]FC in the medium, consistent with reduced ABCA1-dependent cholesterol efflux. 
Accumulation of [3H]FFA was lower in ABCA1-silenced McA cells compared with control cells 
starting at the 12 h time point. Interestingly, the decrease in cellular FFA occurred over a similar 
time course as an increased secretion of [14C]TG into medium, suggesting that incorporation of 
newly synthesized FFA into a secretory pool of TG may be augmented in ABCA1-silenced cells. 
Radiolabeled CE and PL accumulation in cells and medium was similar for control and ABCA1 
silenced cells (data not shown). Collectively, these data suggest that reduced expression of ABCA1 
selectively increases hepatocyte TG secretion. 
Silencing of ABCA1 in McA rat hepatoma cells increases VLDL size 
To explore the effect of ABCA1 silencing on apoB secretion, control and ABCA1-silenced McA 
cells were metabolically radiolabeled with [35S]Met/Cys for 4 h in the presence of oleic acid. 
Newly synthesized apoB48 and apoB100 in the medium was modestly increased by ABCA1 
silencing (∼10–15%) compared with control siRNA (Fig. 2A). Because the ∼2-fold increase in 
VLDL TG secretion (Fig. 1B–D) was associated with only a marginal increase of apoB secretion, 
we postulated that ABCA1 silencing caused the secretion of larger VLDL particles rather than an 
increased number of VLDL particles. To test this, VLDL particle size was measured by dynamic 
laser light scattering. VLDL in medium from cells treated with ABCA1 siRNA averaged 62.7 ± 
4.6 nm in diameter, a 1.6-fold increase relative to VLDL isolated from the medium of control 
siRNA transfected cells (38.7 ± 0.5 nm) (Fig. 2B). To further support these results, cells were 
radiolabeled with [35S]Met/Cys and conditioned medium was fractionated using KBr/NaBr step 
density gradient ultracentrifugation into VLDL1, VLDL2, IDL, LDL, and HDL. Relative to 
control cells, ABCA1 silencing resulted in an increased distribution of apoB100 and apoB48 in 
VLDL1 (Sf 100–400) versus VLDL2 (Sf 20–100) (Fig. 2C). As anticipated from results of previous 
studies (27), some apoB48 is distributed in the HDL fraction of oleate-stimulated McA cells due 
to poor lipidation of apoB48 particles. Together, these data demonstrate that silencing of ABCA1 
in McA cells results in the secretion of larger VLDL particles, suggesting that the second step of 
VLDL assembly is augmented with ABCA1 deficiency. 
Silencing of ABCA1 in McA rat hepatoma cells does not lead to increased LXR 
activation 
We originally hypothesized that a deficiency of ABCA1 will reduce ABCA1-dependent FC efflux, 
which in turn may cause cellular accumulation of oxysterols that are potential endogenous ligands 
for LXRs. LXRs are cholesterol-sensing nuclear receptors that stimulate lipogenic target gene 
expression upon ligand binding, resulting in increased FFA synthesis, elevation of plasma TG, and 
liver steatosis (28, 29). To test whether LXR ligation is increased when ABCA1 is silenced, a LXR 
ligand-binding domain reporter construct was transfected into control and ABCA1-silenced cells. 
Contrary to our expected outcome, endogenous ligation of LXRα was unaffected by ABCA1 
silencing (supplementary Fig. I). As a positive control, the synthetic LXR agonist T0901317 was 
used to stimulate LXR ligation. As expected, T0901317 treatment of cells stimulated LXR binding 
to the reporter construct for control and ABCA1 silenced cells. Surprisingly, LXR binding was 
less in ABCA1-silenced versus control cells. Based on these data, we ruled out the possibility that 
elevated TG secretion in ABCA1 silenced cells is driven by oxysterol-mediated LXR activation. 
Elevated TG secretion in ABCA1-silenced McA rat hepatoma cells is dependent 
on PI3 kinase inhibition 
Increased VLDL secretion can be achieved through inhibition of PI3 kinase activation (30, 31). 
Hence, we determined whether PI3 kinase activation was involved in the increased TG secretion 
from ABCA1-silenced oleate-stimulated McA cells. PI3 kinase p85/55 phosphorylation was 
attenuated by ∼72% in oleate-stimulated ABCA1 silenced cells compared with control siRNA 
treated cells (Fig. 3A). Despite the considerable decrease in PI3 kinase activation in ABCA1-
silenced McA cells, the decrease in phosphorylation of downstream target proteins of PI3 kinase, 
such as PKB/Akt and mTOR, was less robust. The expression of MTP, an essential protein for 
lipid transfer to VLDL (20), remained unchanged (Fig. 3B). 
To determine the extent to which decreased PI3 kinase activation is linked to the increase in TG 
secretion in ABCA1-silenced McA cells, we used two pharmacological inhibitors of PI3 kinase 
activity [Ly 294002 (Ly) and wortmannin]. In the absence of Ly, ABCA1 silencing resulted in a 
2-fold increase in TG secretion compared with control, as expected (Fig. 3C, left panel). In the 
presence of Ly, TG secretion was unchanged for cells treated with ABCA1 siRNA; however, 
control siRNA-treated cells responded to Ly treatment with an increase in TG secretion that was 
similar in magnitude to that of cells treated with ABCA1 siRNA (Fig. 3C, left panel). Similar 
results were observed in wortmannin-treated control and ABCA1-silenced cells (Fig. 3C, right 
panel). These data suggest that silencing of ABCA1 attenuates PI3 kinase signaling to a similar 
degree to that observed with chemical inhibition, resulting in greater VLDL-TG secretion. 
Elevated TG secretion in ABCA1-silenced McA rat hepatoma cells is independent 
of MEK/ERK and mTOR signaling 
Several studies have reported that control of VLDL secretion can be achieved through mTOR (32, 
33) and MEK/ERK signaling (34). We investigated whether MEK/ERK phosphorylation was 
mediating the increase in VLDL-TG secretion when ABCA1 was silenced. Even though ERK was 
decreased with oleate stimulation compared with nonstimulated cells, there was only a small 
decrease in ERK activation in ABCA1-silenced McA cells compared with control cells 
(supplementary Fig. IIA). In addition, inhibition of ERK phosphorylation with a specific 
MEK/ERK inhibitor (U0126) had minimal impact on VLDL-TG secretion relative to the striking 
increase in VLDL TG secretion with ABCA1 silencing (supplementary Fig. IIB). Phosphorylation 
of mTOR appeared reduced in ABCA1-silenced cells compared with control cells (supplementary 
Fig. IIA). Treatment of cells with rapamycin to inhibit mTOR resulted in decreased cellular TG 
and increased TG secretion but failed to abolish the increase in TG secretion caused by ABCA1 
silencing (supplementary Fig. IIC). Taken together, these results suggest that increased TG 
secretion in ABCA1-silenced McA cells is dependent on inhibition of PI3 kinase and minimally 
affected by MEK/ERK or mTOR pathways. 
Pre-β-HDLs generate a PI3 kinase-mediated autocrine signal resulting in reduced 
VLDL TG secretion in McA rat hepatoma cells 
Previously, we demonstrated that incubation of apoA-I with a nonhepatic HEK293 cell line 
expressing ABCA1 is necessary and sufficient for generation of multiple nascent HDL particles 
that vary in size, lipid, and apoA-I content (8). A similar size range of nascent HDL particles was 
also observed when apoA-I was incubated with McA cells (11). We hypothesized that silencing of 
ABCA1 in McA cells results in reduced nascent HDL formation that normally attenuates VLDL 
TG secretion via a PI3 kinase signaling pathway, resulting in increased VLDL TG secretion. 
To test this hypothesis, we used experimental conditions that allowed us to simultaneously analyze 
VLDL TG secretion and nascent HDL formation using [3H]oleate (with 0.4 mM oleate) and 
[125I]apoA-I, respectively, in serum-free medium. Under these conditions, we observed a 2-fold 
increase in radiolabeled TG secretion and a significant decrease in PL secretion (Fig. 4A). The 
decrease in PL secretion from ABCA1-silenced cells may be due to reduced ABCA1-dependent 
PL efflux that is only apparent in serum-free medium. Silencing of ABCA1 did not affect 
electrophoretic mobility of nascent HDL, which was in the pre-β position (Fig. 4B). Separation of 
conditioned medium by NDGGE demonstrated silencing of ABCA1 caused a preferential loss of 
larger nascent HDLs (>10 nm, pre-β3 and pre-β4) and an accumulation of pre-β2 nascent HDL 
(Fig. 4C). These results demonstrate an association between decreased formation of large nascent 
HDLs and increased TG secretion in ABCA1-silenced cells. 
To determine whether the attenuation of PI3 kinase activation and the resulting increase in TG 
secretion in ABCA1-silenced cells could be reversed by exogenously supplied nascent HDL 
particles, conditioned medium containing nascent HDL or nonconditioned medium containing 
only lipid-free apoA-I were separately prepared using cultures of McA cells or empty dishes, 
respectively. Lipid-free apoA-I (non-conditioned medium) did not alter PI3 kinase signaling or 
TG secretion patterns in cells treated with control siRNA (Fig. 5A, lanes 1 and 3; 5B, bars 1 and 
3). However, nascent HDL-containing conditioned medium increased PI3 kinase phosphorylation 
(Fig. 5A, lane 4) and decreased TG secretion (Fig. 5B, bar 4) to levels observed in control siRNA-
treated cells. To rule out the possibility that decreased radiolabeled TG in McA cell-conditioned 
medium was due to lipolysis, lipase activity in medium was measured using [3H]triolein emulsion 
particles as substrate (35). The absence of lipase activity above background levels in McA cell-
conditioned medium (data not shown) suggested that the decrease in radiolabeled TG in the 
medium of ABCA1-silenced cells was due to secretion and not lipolysis. Collectively, these data 
suggest the existence of a novel signaling pathway in which nascent HDLs generated by ABCA1 
attenuate VLDL TG secretion. 
Larger nascent HDLs selectively decrease VLDL TG secretion 
Next, we addressed two fundamental questions regarding the ability of nascent HDLs to attenuate 
VLDL TG secretion: 1) is this a unique property of nascent HDLs of hepatic origin, and 2) are 
different-sized nascent HDLs equally effective in reducing TG secretion? 
To answer the first question, conditioned medium of nonhepatic origin was prepared from 
ABCA1-expressing or control HEK293 cells, followed by addition of conditioned medium to 
oleate-stimulated control and ABCA1-silenced McA cells. In the absence of conditioned medium, 
ABCA1-silenced cells demonstrated increased TG secretion, as anticipated (Fig. 6A, first two 
bars). Similar results were obtained when conditioned medium from control HEK293 (i.e., not 
expressing ABCA1) cells was added to ABCA1-silenced McA cells (Fig. 6A, bars 3–4). However, 
when conditioned medium from ABCA1-expressing HEK293 cells was added to ABCA1-silenced 
McA cells, TG secretion was reduced to the levels observed in control siRNA-treated cells (Fig. 
6A, bars 5–6). Hence, the ability to reduce TG secretion was not a unique property of nascent HDL 
of hepatic origin. In addition, this experiment excludes the possibility that the results obtained in 
Fig. 5B were due to an unidentified secretory factor(s) from McA cells that was responsible for 
lowering TG secretion. 
To address whether all nascent HDL subfractions are equally effective in reducing TG secretion 
in ABCA1-silenced McA cells, we fractionated conditioned medium from ABCA1-HEK293 cells 
by FPLC and isolated and concentrated individual nascent HDL species (pre-β1–5). Individual 
(pre-β1, 2, 3) or pooled (pre-β4 and 5) nascent HDL were incubated with oleate-stimulated control 
and ABCA1-silenced McA cells. The larger (>10 nm; pre-β 3, 4, and 5) nascent HDL significantly 
attenuated TG secretion, whereas the smaller pre-β1 and 2 particles had no significant impact on 
TG secretion (Fig. 6B). 
Finally, to determine whether cell-free assembly of model nascent HDL particles (i.e., rHDL) 
would also attenuate TG secretion in ABCA1-silenced McA cells, we incubated small rHDL 
(rHDLsm <10 nm) and large rHDL (rHDLlg >10 nm) as well as human plasma HDL with control 
and ABCA1-silenced McA cells and measured TG secretion and PI3 kinase activation. rHDLsm 
were heterogeous in size, ranging between 7.1 and ∼8.2 nm, and rHDLlg were composed of two 
major particles, 17 and 10 nm (Fig. 7A, left panel). As anticipated, both rHDLs migrated in the 
pre-β range on agarose gels, whereas hHDL migrated in the α position (Fig. 7A, right panel). 
Addition of rHDL particles, but not hHDL, resulted in a significant reduction in TG secretion 
relative to lipid-free apoA-I in ABCA1-silenced McA cells, with a greater reduction in TG 
secretion observed with rHDLlg compared with rHDLsm (Fig. 7B). Furthermore, reduced PI3 
kinase activation in ABCA1-silenced McA was restored with rHDL incubation, but not with lipid-
free apoA-I or hHDL (Fig. 7C). Based on these combined results, we propose that large nascent 
HDLs assembled by ABCA1 generate an autocrine signal that contributes to diminished TG 
secretion. 
Discussion 
The goal of this study was to determine the role of hepatic ABCA1 expression in the regulation of 
VLDL TG secretion. Although we now understand how absence of ABCA1 function leads to low 
plasma HDL concentrations in Tangier subjects, a molecular explanation for the increased plasma 
TG concentrations in these patients is not clear. One suggestion is that apoC-III and apoA-II 
enrichment of VLDL inhibits intravascular lipolysis of VLDL, resulting in increased plasma TG 
concentrations (14). However, this hypothesis has not been rigorously tested. An alternative 
unexplored hypothesis is that hepatic overproduction of VLDL leads to elevated plasma TG 
concentrations. Individuals with type 2 diabetes have a plasma lipid phenotype similar to that of 
Tangier disease heterozygotes, including increased plasma TG, decreased plasma HDL, and a 
predominance of smaller HDL particles in plasma (12, 13, 36). Type 2 diabetics also have 
overproduction of larger TG- enriched VLDL1 particles with little change in smaller VLDL2 
particles (37). In addition, cells from Tangier subjects have a defect in Golgi-to-plasma-membrane 
vesicular trafficking that potentially could affect VLDL secretion (38). These observations led us 
to hypothesize that the increase in plasma TG in the absence of ABCA1 may result from hepatic 
overproduction of VLDL. This hypothesis was particularly attractive because hepatocytes are a 
quantitatively important cell type in both VLDL and HDL production. In this study, we 
demonstrate that silencing of ABCA1 in McA cells results in decreased formation of large nascent 
HDL particles with concomitant increase in smaller nascent HDLs, increased secretion of large 
VLDL1 particles, and attenuated PI3 kinase activation. Furthermore, addition of large nascent pre-
β-migrating HDL particles to ABCA1-silenced cells results in decreased TG secretion and 
increased PI3 kinase activation, suggesting a novel pathway in which hepatic ABCA1 regulates 
VLDL TG secretion through PI3 kinase-dependent HDL signaling. 
Assembly of apoB with lipid to form VLDL particles in the liver is a complex process composed 
of at least two distinct steps. The first step involves cotranslational apoB lipidation by MTP 
forming a small dense primordial apoB-containing preVLDL in the endoplasmic reticulum (20, 
39). This preVLDL fuses with lipid droplets in the endoplasmic reticulum or Golgi compartments 
(i.e., second step), maturing into a VLDL-sized particle referred to as VLDL2 (Sf 20–100) (40). 
Available evidence suggests that MTP is also required for generation of the second step lipid 
droplets (20, 41–43). If sufficient TG is available in the secretory compartment, second step 
assembly can result in larger TG-enriched VLDL1 particles (Sf 100–400) that is one of the 
hallmarks of type 2 diabetes (44). The second step of VLDL assembly is inhibited by PI3 kinase 
activation, such that inhibitors of PI3 kinase (i.e., wortmannin and Ly 294002) enhance second 
step assembly and secretion of larger TG-enriched VLDL1 particles (30, 31). Our results suggest 
that silencing of ABCA1 in McA cells selectively augments second step VLDL assembly based 
on the following observations: 1) secretion of larger TG- enriched VLDL1 particles with a minimal 
increase in VLDL particle number (Fig. 2), 2) decreased PI3 kinase phosphorylation (Fig. 3A), 
and 3) insensitivity of TG secretion to PI3 kinase inhibitors in ABCA1 silenced cells (Fig. 3C). 
Insulin diminishes VLDL secretion through several signaling pathways, including MEK/ERK (30, 
45) and PI3 kinase pathways (30, 31, 46, 47). Insulin stimulation appears to specifically inhibit the 
second step of VLDL assembly such that insulin resistance results in increased hepatic production 
of VLDL1 (37). Most of insulin's inhibitory effect on VLDL secretion appears to be at the level of 
MTP expression (48, 49). Recently, Kamagate et al. (50) reported that MTP is a target of the 
transcription factor forkhead box O1 (FoxO1) and that signaling through IRS-1/PI3K/Akt results 
in phosphorylation of FoxO, which induces translocation of FoxO1 from the nucleus to the cytosol 
and results in decreased transcriptional activation of the MTP gene. In addition, insulin-mediated 
MEK/ERK activation causes inhibition of MTP activity, limiting TG availability and apoB 
stability in HepG2 cells (51, 52). However, these pathways do not explain the increased TG 
secretion with silencing of ABCA1 since MTP expression was similar (Fig. 3) and MEK/ERK 
activation (supplementary Fig. II) was minimally affected in ABCA1-silenced McA cells versus 
control siRNA-treated cells. 
mTOR is a serine/threonine kinase that regulates multiple cellular functions and acts as a sensor 
of cellular nutrient and energy levels (53). Rapamycin is an inhibitor of mTOR and is used 
clinically as an immunosuppressive drug to reduce the risk of kidney transplant rejection. A 
significant side effect of rapamycin treatment is hyperlipidemia that involves hepatic 
overproduction of TG (32, 33). Rapamycin treatment of McA cells did not affect the increased TG 
secretion observed in ABCA1 versus control siRNA-treated cells (supplemental Fig. IIC), 
suggesting that the mTOR pathway was not responsible for the increased TG secretion in ABCA1-
silenced cells. 
Another possible explanation for increased TG secretion in ABCA1-silenced McA cells may relate 
to an increase in an intracellular pool of cholesterol that stimulates VLDL secretion. In support of 
this concept, Khan et al. (54) reported that inhibition of cholesterol biosynthesis in rats given statin 
treatment resulted in a decrease in intracellular cholesterol and a significant decrease in VLDL TG 
secretion. In addition, Sahoo et al. (15) showed that apoA-I-dependent ABCA1 cholesterol efflux 
was associated with decreased TG secretion in primary mouse and rat hepatocytes and McA cells. 
Taken together, these studies suggest a regulatory pool of cholesterol may be involved in 
controlling VLDL TG secretion. Our results do not support an increase in cellular FC or CE content 
in ABCA1-silenced cells, although appearance of FC in the medium was decreased (Fig. 1D). 
However, this does exclude the possibility that a small regulatory pool of cholesterol might not be 
detected by our experimental procedures. For instance, a small increase in cellular FC in ABCA1-
silenced cells may result in an increase in one or more oxysterols that could activate LXR and 
increase TG synthesis (28, 55). However, we did not observe an increase in cellular TG synthesis 
(Fig. 1B) and could find no evidence for increased LXR activation in ABCA1-silenced cells 
(supplementary Fig. I), suggesting that LXR activation does not explain our experimental results. 
Because ABCA1 has no known role in TG transport, we hypothesized that silencing of ABCA1 
reduced nascent HDL production, which in turn resulted in increased TG secretion. In support of 
our hypothesis, addition of nascent HDL particles or rHDLs to ABCA1-silenced McA cells 
reduced TG secretion (Figs. 5–7).). Furthermore, reduction in TG secretion occurs with the 
addition of nascent HDL particles generated by hepatic as well as nonhepatic cell lines and larger 
nascent HDL particles are more potent in reducing TG secretion compared with smaller ones (Fig. 
6, ,7).7). This trend was also observed for rHDL particles (Fig. 7B). There is a well-accepted 
inverse relationship between plasma HDL and TG concentrations in the general population. This 
relationship is also observed in heterozygous Tangier disease subjects (12). The extent to which 
low HDL concentrations in individuals with ABCA1 polymorphisms is linked to elevated plasma 
TG concentrations in these same subjects is unknown. However, our data suggest that there may 
be a direct link as summarized in Fig. 8. Heterozygous Tangier disease subjects have fewer large 
HDL particles in plasma. Our results suggest that this may be due to decreased hepatic ABCA1 
function, resulting in decreased assembly of large nascent HDL particles (Fig. 4C). We 
hypothesize that these particles normally transmit signals through a PI3 kinase-mediated pathway 
to decrease VLDL TG secretion (Fig. 8, left). We speculate that a putative receptor for pre-β HDL 
particles (i.e., Topβ, target of pre-β HDL) transmits the signal to activate PI3 kinase and reduces 
lipid mobilization for VLDL secretion, and that larger pre-β migrating HDL particles preferentially 
interact with the putative Topβ. In situations of diminished ABCA1 function, large nascent HDL 
particles are reduced in concentration (Fig. 4C), resulting in diminished PI3 kinase activation (Fig. 
5A, ,7C),7C), increased lipid mobilization, and increased VLDL TG secretion (Fig. 8, right). 
Another explanation for the inverse relationship between plasma HDL and TG in humans and 
animal species that express active cholesteryl ester transfer protein relates to intravascular 
metabolism. Cholesteryl ester transfer protein can exchange TG in VLDL for CE in HDL, followed 
by lipolysis of the TG in HDL by hepatic lipase (56, 57). This results in smaller HDL particles and 
the generation of pre-β HDL. Thus, when TG concentrations and/or cholesteryl ester transfer 
protein activity are elevated, HDL concentrations are reduced. 
In summary, our data suggest a novel pathway in which hepatic ABCA1 regulates VLDL TG 
secretion through PI3 kinase-dependent nascent HDL signaling. This pathway may contribute to 
the inverse association between reduced plasma HDL and increased plasma TG concentrations in 
individuals with compromised ABCA1 function due to genetic mutations in ABCA1 or other 
metabolic conditions that compromise nascent HDL assembly by hepatocytes. 
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siRNA-induced silencing of ABCA1 increases VLDL TG secretion in rat hepatoma cells. A: 
McA rat hepatoma cells were transfected with either ABCA1 siRNA (0–100 nM) or two control 
siRNAs for 72 h. Silencing efficiency was assessed by Western blot analysis for ABCA1 
expression. All subsequent experiments used 25 nM siRNA to silence ABCA1. B: Control and 
ABCA1 siRNA transfected McA cells were incubated with radiolabeling medium (10% FBS, 5 
μCi/ml 3H-oleate + 0.8 mM oleate) for 24 h. Lipids were extracted from medium and cells, 
fractionated by TLC, and radiolabeled TG quantified by liquid scintillation spectroscopy. 
Cellular protein was quantified and radiolabeled TG content was expressed as 3H-TG dpm/μg 
cell protein (n = 3). C: Conditioned medium (500 µl; pooled, n = 3) from the experiment in B 
was fractionated by fast protein liquid chromatography and radiolabel in each fraction was 
determined. VLDL elution position (fractions 30–35) is denoted. D: Control and ABCA1 siRNA 
transfected McA cells were radiolabeled with [14C]glycerol (1μCi/ml) and [3H]acetate (5μCi/ml) 
in the presence of 0.8 mM oleate and cell and medium was harvested at 0, 1, 3, 6, 12, and 24 h. 
Lipids were extracted from cells and medium and separated into individual lipid classes by TLC, 
followed by radiolabel quantification in individual lipid classes by liquid scintillation 
spectroscopy. FC, free cholesterol; TG, triglyceride. ABCA1 siRNA, closed circle and dashed 
line; control siRNA, open circle and solid line. Results are expressed as mean ± SEM of 




Silencing of ABCA1 promotes secretion of larger VLDL (i.e., VLDL1) with minimal increase in 
total apoB secretion. Control and ABCA1 siRNA-transfected McA cells were metabolically 
radiolabeled with [35S]Met (50μCi/ml) for 4 h in the presence of 0.8 mM oleate. A: Conditioned 
medium was immunoprecipitated with antibody to apoB. The immunoprecipitated proteins were 
separated by 4–8% SDS-PAGE and visualized with a phosphorimager. Relative intensities (mean 
± range) of apoB100 and apoB48 were quantified and are shown under the image. AU, arbitrary 
units. B: VLDL from conditioned medium was floated by ultracentrifugation at d = 1.006g/ml 
and particle size was measured by dynamic laser light scatter. Results are expressed as mean ± 
SEM of triplicate analyses. ** (P < 0.01). C: [35S]Met radiolabeled conditioned medium was 
subjected to density gradient ultracentifugation to fractionate the indicated lipoprotein species. 
ApoB was immunoprecipitated from one ml of individual or pooled fractions, the 
immunoprecipitated proteins were separated by SDS-PAGE and radiolabel in protein bands was 
visualized using a phosphorimager. Because fractions 4–6, 7–9, and 10–12 were pooled (i.e., 3 
ml total), the volume equivalent for each lane on the gel is indicated below the fraction number. 
Positions of lipoprotein classes in the gradient are denoted at the top of the gel and migration 
positions of apoB100 and apoB48 are shown on the right side of the gel image. VLDL1 = Sf 
100–400, VLDL2 = Sf 20–100. Images were quantified using a phosphorimager and relative 
intensities of apoB (B100 + B48) in individual or pooled fractions are presented as a percentage 
distribution in the gradient. Intensities for the pooled fractions were multiplied by three to correct 




ABCA1 silencing is associated with decreased activation of PI3 kinase and increased TG 
secretion. Control and ABCA1 siRNA transfected McA cells were incubated with 0.8 mM oleate 
for 24 h. A: PI3 kinase activation was determined by Western blot analysis of p-PI3 kinase 
p85/p55. Data represent mean ± SEM for three samples obtained in two separate experiments. B: 
Cells were harvested and Western blotted for ABCA1, p-PI3 kinase p85/p55, p-AKT, p-mTOR, 
MTP, and β-actin (loading control) as indicated. C: Control or ABCA1 siRNA transfected McA 
cells were incubated with vehicle (DMSO), LY294002 (10 μM), or wortmannin (100 nM) as 
indicated for 1 h before addition of radiolabeling medium ([3H]oleate (5 μCi/ml) + 0.8 mM 
oleate). After additional 12 h incubation, lipids were extracted from medium and radiolabel 
incorporation into TG was quantified by TLC. Data (mean ± SEM, n = 3–4) were normalized to 




Silencing of ABCA1 results in decreased formation of large pre-β HDL concomitant with 
increased TG secretion. Control and ABCA1 siRNA transfected McA cells were incubated with 
[3H]oleate (5 µCi/ml) and [125I]apoA-I (10 µg/ml; 105 cpm/µg) in the presence of 0.4 mM oleate 
in serum-free medium for 24 h. A: ABCA1 expression levels were assessed by Western blot 
analysis (top). Aliquots of conditioned medium were lipid extracted, lipids (PL, TG, and CE) 
were separated by TLC, and [3H]oleate incorporated into the lipid fractions was determined 
(mean ± SEM, n = 4). B: Conditioned media and lipid-free [125I]apoA-I were separated on 
agarose gels and radioactivity was visualized using a phosphorimager. Human HDL and LDL 
were used as markers of α and β migration. C: Aliquots (15µl) of conditioned medium were 
fractionated by NDGGE and nascent HDL particles were visualized using a phosphorimager. 
Nascent pre-β migrating HDL formation was quantified by phosphorimager analysis and 
normalized to control siRNA transfected McA cells for each pre-β HDL fraction. Results are 
expressed as mean ± SEM of triplicate gels. Image is representative data from three independent 




Increased TG secretion in ABCA1 silenced McA cells is attenuated by nascent HDL-containing 
conditioned medium. Conditioned McA medium (+ McA CM) was prepared by incubating 10 
μg/ml of apoA-I with McA cells for 24 h; nonconditioned medium (− McA CM) was prepared 
by incubating the same concentration of apoAI in empty dishes. Conditioned or nonconditioned 
medium was then transferred to McA cells that had been previously transfected with control or 
ABCA1 siRNA and cells were then stimulated with 0.4 mM oleate in serum-free radiolabeling 
medium (containing 5 μCi/ml [3H]oleate) for an additional 12 h. Cells were harvested for 
Western blot analysis (A) and the medium was harvested to determine the extent of [3H]oleate 
incorporation into secreted TG (B). A: ABCA1 and p-PI3K p85/p55 expression by Western blot 
analysis. NS, non-specific band used as load control. B: [3H]TG secretion from control or 
ABCA1 siRNA-treated McA cells after incubation with conditioned medium from McA cells or 
nonconditioned medium for 12 h. Results are representative of two separate experiments and are 





Large nascent HDLs attenuate the increased TG secretion induced by ABCA1 silencing. A: 
Conditioned medium was prepared by incubating 10 μg apoA-I /ml with control and ABCA1-
expressing HEK 293 cells for 24 h. Nonconditioned medium (−CM) was prepared by incubating 
10 µg/ml of apoA-I with empty dishes for 24 h. The conditioned or nonconditioned medium 
along with [3H]oleate + 0.4 mM oleate was then added to McA cells that had been previously 
transfected with control or ABCA1 siRNA (25 nM for 48 h). After additional 12 h incubation, 
[3H]TG secretion into the medium was quantified as described in Fig. 1 legend. B: Conditioned 
medium from ABCA1-expressing HEK293 cells was prepared as described in A and fractionated 
by high resolution FPLC into individual subfractions of nascent HDL as described previously 
(8). McA cells that had been previously transfected with control or ABCA1 siRNA (25 nM for 
48 h) were incubated with individual nascent HDL subfractions (2 µg protein/ml) in the presence 
of [3H]oleate + 0.8 mM oleate for an additional 12 h and the amount of newly synthesized TG 
secreted into the medium was quantified. Results are normalized to control siRNA transfected 
cells and are expressed as mean ± SEM of triplicate analyses. ** (P < 0.01), *** (P < 0.001); ns, 




Large rHDL, but not hHDL, attenuate TG secretion in ABCA1-silenced McA cells. A: Small 
(rHDLsm) and large (rHDLlg) recombinant HDL and human HDL were characterized for size by 
NDGGE (left) and electrophoretic mobility by agarose gel electrophoresis (right). Proteins were 
visualized by Coomassie Brilliant Blue G-250 staining. B: Control or ABCA1 siRNA transfected 
(25 nM for 48 h) McA cells were incubated with 10µg protein/ml of either lipid-free apoA-I (LF-
AI), rHDL, or hHDL in the presence of [3H]oleate + 0.8 mM oleate for 12 h and the amount of 
newly synthesized TG secreted into the medium was quantified. C: Cellular protein from the 
experiment in B was harvested and ABCA1 and p-PI3K p85/p55 expression was examined by 
Western blot analysis. Western blot data for control siRNA rHDL incubations were similar to 
that for the lipid-free apoA-I incubation and are not shown. ** (P < 0.01), *** (P < 0.001); ns, 




Summary diagram of experimental results. In the presence of active ABCA1 (left), lipid free 
apoA-I is secreted by hepatocytes and lipidated by hepatocyte ABCA1, forming nascent HDL 
particles. Large nascent HDLs (>10 nm diameter) bind to a putative receptor (Topβ, target of 
pre-β), which in turn stimulates PI3 kinase activation and results in reduced lipid mobilization 
and secretion of normal-sized VLDL particles (i.e., VLDL2). In contrast, in the absence of 
hepatic ABCA1 or diminished ABCA1 activity (right), newly secreted lipid-free apoA-I fails to 
form large nascent HDL particles. The absence of large nascent HDL particle formation leads to 
diminished signaling through Topβ, resulting in reduced PI3 kinase activation, increased lipid 
mobilization, and increased secretion of larger TG-enriched VLDL particles (VLDL1). 
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Figure 8. Summary diagram of experimental results. In the presence of active ABCA1 (left), lipid free 
apoA-I is secreted by hepatocytes and lipidated by hepatocyte ABCA1, forming nascent HDL particles. 
Large nascent HDLs (>10 nm diameter) bind to a putative receptor (Topβ, target of prebeta), which in 
turn, stimulates PI3 kinase activation and results in reduced lipid mobilization and secretion of normal-
sized VLDL particles (i.e., VLDL2). In contrast, in the absence of hepatic ABCA1 or diminished ABCA1 
activity (right), newly secreted lipid-free apoA-I fails to form large nascent HDL particles. The absence of 
large nascent HDL particle formation leads to diminished signaling through Top, resulting in reduced 
PI3 kinase activation, increased lipid mobilization, and increased secretion of larger TG-enriched VLDL 
particles (VLDL1).   
 
Supplemental Figure 1. ABCA1 silencing does not increase endogenous LXR ligand binding activ-
ity in rat hepatoma cells.  Control and ABCA1-silenced McA cells were transiently cotransfected with: 
1) GAL4-driven luciferase reporter construct (pMH100X-TK-Luc), 2) an expression vector containing the 
Gal4 DNA binding domain fused to the LXR ligand binding domain (pCMX-Gal4-LXRαLBD), and 3) a 
control vector (pRL-CMV). Cultures were stimulated with either oleate (0.8 mM) or LXR agonist (posi-
tive control, 5 M T0901317) overnight before a dual luciferase assay was performed. Results are repre-
sentative of two separate experiments and are expressed as mean ± SEM (n=4). ***, (p<0.001) by stu-
dent’s t-test.  
 
Supplemental Figure 2. ERK and mTOR activation is not responsible for elevated TG secretion in 
ABCA1-silenced McA cells.  A. Control and ABCA1 siRNA transfected McA cells were incubated ± 0.8 
mM oleate for 12 h. Cell lysates were then harvested and Western blotted for p-ERK, t-ERK and p-
mTOR. B. Control and ABCA1 siRNA transfected McA cells (25 nM for 48 h) were preincubated with 
10 nM U0126 (inhibitor of ERK activation) for 1 h before addition of radiolabeling medium (5 Ci/ml 
[3H]-oleate + 0.8 mM oleate), followed by an additional 12 h incubation. Conditioned medium (500 µl; 
pooled n=3) was fractionated by FPLC and radiolabel in each fraction was determined. VLDL elution 
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position (fractions 30-35) is denoted. C. Control or ABCA1 siRNA transfected McA cells were incubated 
with vehicle (DMSO) or 10 µM rapamycin (RAPA) for 1 h before addition of radiolabeling medium (5 
Ci/ml [3H]-oleate + 0.8 mM oleate). After an additional 12 h incubation, cells and medium were lipid 
extracted, radiolabel incorporation into TG was quantified by thin-layer chromatography, and the data 
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